Download 0910_Thrombinoscope-acquisition.doc

FOR IMMEDIATE RELEASE

Contact:
Paul Riley, PhD
Manager, Research Use Products
(973) 631-1200
Paul.Riley@stago-us.com

Stago Establishes Stake in Thrombin Generation Through Acquisition of Thrombinoscope BV

September 23, 2010, Parsippany, NJ — Diagnostica Stago, Inc. (DSI), recently finalized the acquisition of Thrombinoscope BV, based in Maastricht, The Netherlands. This company, originally developed at Maastricht University, researches, develops and markets thrombin generation (TG) systems through the use of the Calibrated Automated Thrombogram® (CAT) system. This system is available for research-only use – it should not be used for diagnostic procedures.

“The development potential of this new TG approach in hemostasis using the CAT system is very promising,” noted Stephane Zamia, PhD and CEO of DSI. “The addition of this approach to Stago’s portfolio will allow our customers to measure TG in real-time and in larger, scalable studies.”

Operations and research at the company will remain independent within the Stago Group, and will report directly to the company’s Scientific and Clinical Department. The Stago Group believes that by remaining independently controlled, this start-up company will continue nascent creativity leading to product innovation, citing their recent acquisition of BioCytex, a company specializing in standardized kits for flow cytometric analysis of blood cells.

What is Thrombin generation (TG)?
TG is a universal test capable of assessing a patient’s global hemostatic balance in the case of hemorrhage or thrombosis. Few methods previously existed that allowed for TG standardization and calibration. Thrombinoscope introduced a patented, sample-specific calibrator that allows for error correction due to inter-subject plasma composition and color variations, as well as substrate consumption. This method is both specific and sensitive, thus giving increased relevance to this hemostatic test in academic research centers, pharmaceutical companies and contract research organizations.

Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France, a leader in the development and manufacture of Hemostasis products. For more information about any Stago product or service, please call 800-222-COAG or visit our website at www.stago-us.com.

###